Breast Cancer

Despite the emergence of PARP inhibitors, antibody-drug conjugates (ADCs), and immunotherapy in the treatment of patients with triple-negative breast cancer (TNBC), more work is needed to propel further progress, according to Kevin Kalinsky, MD, MS.

Combining ovarian suppression and an aromatase inhibitor is an efficacious treatment method for premenopausal women with breast cancer. However, the regimen (which is given long-term) can cause some major adverse events, explained Dawn L. Hershman, MD, MS, professor of medicine and epidemiology at the Columbia University Irving Medical Center.

The role of radiation therapy, specifically with elective nodal irradiation (ENI), has evolved over the past several years, said He James Zhu, MD, PhD, adding that the technique should be performed in patients with breast cancer on an individualized basis.

Research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) had a significant effect on the standard of care for patients with HER2-positive metastatic breast cancer, explained Erika P. Hamilton, MD.

Frequent communication between patients and providers is key in getting ahead of adverse events that can occur during breast cancer treatment, explained Madeline Kuiper, MSN, RN, OCN, an oncology nurse practitioner at UCLA.

While the regimen was overall well tolerated, there are some adverse events for nurses to look out for.

The FDA has accepted a biologics license application (BLA) to review eflapegrastim (Rolontis) for the management of chemotherapy-induced neutropenia, according to Spectrum Pharmaceuticals, the developer of the novel long-acting granulocyte-colony stimulating factor (G-CSF).

The FDA has accepted a biologics license application (BLA) for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer (TNBC) who have received at least 2 prior therapies for metastatic disease, according to a statement from the company developing the antibody-drug conjugate (ADC), Immunomedics.

The FDA has approved the use of Trastuzumab Deruxtecan for the treatment of patients with HER2+ Breast Cancer, based on recent findings.

The FDA has granted tucatinib a breakthrough therapy designation for use in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, who had prior trastuzumab, pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1; Kadcyla).

It is important that nurses talk with their patients about what kind of adverse events to expect while being treated for HER2-positive breast cancer.

Residual cancer burden (RCB) after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes, according to data from a large meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium.

A durvalumab (Imfinzi)-based neoadjuvant regimen induced a pathologic complete response (pCR) rate of 44% in patients with triple-negative breast cancer (TNBC), according to results of a phase I/II study presented in a poster at the 2019 San Antonio Breast Cancer Symposium.

Real-world clinical practice results for frontline palbociclib (Ibrance) indicate that the positive progression-free survival (PFS) data previously reported with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival (OS) benefit in patients with HR-positive/HER2-negative metastatic breast cancer.

Trastuzumab deruxtecan had an ORR rate of nearly 61% for patients with advanced HER2-positive breast cancer.

The FDA has approved 2 abbreviated new drug applications (ANDAs) for everolimus (Afinitor) tablets for the treatment of patients numerous malignancies.

Resistance to aromatase inhibitors (AIs) is a growing concern in patients with advanced hormone receptor (HR)–positive, HER2-negative breast cancer, said Hope S. Rugo, MD, FASCO, who added that although fulvestrant (Faslodex) has shown some activity in patients who develop ESR1 mutations, more effective treatment options are needed.

Drug prices for cancer care are rising considerably, but biosimilars are poised to help patients with cancer handle these prices. Particularly, patients with breast cancer.

While physicians are looking to further subclassify TNBC to narrow treatment options, not all of these classifications are actionable in the clinic.

Multiple CDK4/6 inhibitors have shown impressive OS survival benefit in multiples studies of patients with metastatic HR+ breast cancer.

Despite advanced technology and new treatment breakthroughs in cancer care, treatment disparity remains among African American women with breast cancer.

At the 2019 ESMO Congress, the phase II KATE2 trial missed its primary endpoint but found promising results for a subgroup of patients with HER2-positive breast cancer with a PD-L1 expression.

Immunotherapy is sometimes considered solely for the later stages of treatment, but findings from a new study show promise for immunotherapy in treating patients with early breast cancer.

One expert details why axillary lymph node dissection is vital in the treatment of patients with breast cancer.

By implementing a survivorship program at their cancer center, oncology nurses were able to improve the quality of life in patients with recurrent breast cancer.

Patients with the highest risk of developing a BRCA mutation are not being tested earlier enough and developing these mutations when it's too late. Clinicians can change that.

The FDA has granted a priority review for Trastuzumab Deruxtecan to treat HER2-positive metastatic breast cancer based on the results from two new studies.

At the 2019 ESMO Congress, results for the MONALEESA-3 trial showed promise for patients with breast cancer and had many experts excited over its clinical implications.

The future of treating patients with triple-negative breast cancer is bright, but more needs to be done to address mutations early on in the course of the disease.

Overall survival results from the MONALESSA-3 phase III trial showed positive results for patients with advanced breast cancer, but toxicities related to the use of ribociclib still need to be addressed.